Oncology

Inhibiting a previously undruggable protein holds promise for treatment of numerous types of cancer.

Longer telomeres gives cancer cells a survival advantage.

Kjel Jonhson, PharmD, Vice President of Global Oncology for IMS Health, discusses innovative new therapies for the treatment of cancer.

Ibrutinib found to control Waldenstrom's Macroglobulinemia in 95% of patients.

Analysis of cancer-causing mutations in the BRCA1 or BRCA2 genes may lead to more effective treatments.

Study finds that UV tanning meets the same criteria as smoking as a cause of cancer.

Enzyme blocker reduces growth of intestinal tumors.

Prevalence of tanning linked to sharp increase in melanoma risk.

Private insurers and Medicare patients can pay up to 43 times less than the uninsured.

Enzyme blocker shows potential in treating infections such as Ebola virus.

Glioblastoma Multiforme treatment may extend current one year survival rate.

Drug could eventually also treat prostate cancer.

Drug failed in treatment of solid tumors but shows promise blocking amyloid-beta plaques.

Natural extract found to reduce cell growth in triple negative breast cancer.

Less toxic drug class combined with fasting may kill breast, lung, and colon cancer cells equally well.

Engineered protein improves survival rates in aggressive leukemia.

Crohn's disease specifically carries greater risk for developing cervical cancer.

Donna M. Smith, PharmD, director of clinical affairs at Avella Specialty Pharmacy discusses strategies for the management of new lung cancer treatment options.

Compounds that prevent protein aggregation may lead to therapy for conditions such as cancer and diabetes.

Standard chemotherapy plus bevacizumab extends survival by a median of 5 months.

Kyprolis has already been approved for patients who failed at least 2 previous therapies.

Researchers believe drug will lead to ‘new paradigm' in leukemia therapy.

Scalp cooling technology seeks to ensure hair retention in most instances.

Blood test may identify patients who need more intensive chemotherapy.

Teikoku Pharma USA has submitted a New Drug Application to the FDA for the product.

Current smokers and those who quit less than 10 years prior to surgery face twice the risk of disease recurrence.

Genetic changes in tumors linked to immune system response to disease.

Costs have risen 120% in aggregate since 1995.